Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70353 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Yi-Wei Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Second Primary. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Health Promotion Administration, Ministry of Health and Welfare in Taiwan, Health Promotion Administration, Ministry of Health and Welfare.
Abstract (Originalsprache)
While second primary malignancies (SPMs) in Western patients with chronic lymphocytic leukaemia (CLL) are well documented, data from Asian populations remain limited. This nationwide, retrospective cohort study assessed SPM risk in 2702 CLL patients diagnosed in Taiwan between 1991 and 2020 using the Taiwan Cancer Registry. Standardized incidence ratios (SIRs), absolute excess risks and cumulative incidences were calculated relative to the general population, stratified by sex, age, latency and treatment. The overall SPM risk was elevated (SIR, 1.14, 95% confidence interval [CI], 1.00–1.29), with a 5‐year cumulative incidence of 6.53%. Notably increased risks were observed for epithelial skin cancer (SIR, 2.55; 95% CI, 1.60–3.86) and urinary bladder cancer (SIR, 1.99; 95% CI, 1.06–3.41). A lower risk of breast cancer was detected among younger women (SIR, 0.29; 95% CI, 0.06–0.85). SPM risk was highest within 5 years of CLL diagnosis (SIR, 2.72; 95% CI, 2.27–3.22) and then decreased thereafter (SIR, 0.67; 95% CI, 0.56–0.81). These findings reveal a distinct SPM risk profile among Asian CLL patients, particularly the excess risk of bladder cancer, underscoring the importance of tailored surveillance strategies for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
- Taiwan Cancer Registry Center, Taipei, Taiwan.
- Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung City, Taiwan.
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery, and Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
ORCID-Profile: Chun-Ju Chiang, Shang-Ju Wu
Förderung
- Health Promotion Administration, Ministry of Health and Welfare in Taiwan
- Health Promotion Administration, Ministry of Health and Welfare
Zitieren
APA
Lee, Y. W., Chiang, C. J., Lin, Y. C., Tzeng, H. E., Chuang, Y. T., Yang, Y. W., Lee, W. C., & Wu, S. J. (2026). Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study. British Journal of Haematology. https://doi.org/10.1111/bjh.70353
Vancouver
Lee YW, Chiang CJ, Lin YC, Tzeng HE, Chuang YT, Yang YW, et al. Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study. British Journal of Haematology. 2026. doi:10.1111/bjh.70353
BibTeX
@article{Lee2026,
author = {Lee, Yi-Wei and Chiang, Chun-Ju and Lin, Ying-Chu and Tzeng, Huey-En and Chuang, Yi-Ting and Yang, Ya-Wen and Lee, Wen-Chung and Wu, Shang-Ju},
title = {Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70353}
}
EUVIMED